Womenʼs experiences of induction of labour with misoprostol tablets compared with vaginal insert

Autor: Hansen, K. H., Eriksson, A., Jeppesen, S., Jeppegaard, M., Lone Krebs

Publikováno v: Hansen, K H, Eriksson, A, Jeppesen, S, Jeppegaard, M & Krebs, L 2023, ' Womenʼs experiences of induction of labour with misoprostol tablets compared with vaginal insert ', Danish Medical Journal, vol. 70, no. 2, A04220232 . < https://ugeskriftet.dk/dmj/womens-experiences-induction-labour-misoprostol-tablets-compared-vaginal-insert >
University of Copenhagen
Scopus-Elsevier

INTRODUCTION. The aim of this study was to compare nulliparous women’s experiences with induction of labour using two different regimens of misoprostol. METHODS. We adapted a validated questionnaire regarding experience with induced labour. In two

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::76b3c9baa7ccb957edcb045106576082
https://curis.ku.dk/portal/da/publications/womens-experiences-of-induction-of-labour-with-misoprostol-tablets-compared-with-vaginal-insert(9f2c6201-6772-4f94-a9ce-be6a57a52b1f).html

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations:a post-hoc subgroup analysis with pooled data from two phase II clinical trials

Autor: Eide, I. J. (Inger Johanne Zwicky), Stensgaard, S. (Simone), Helland, Å. (Åslaug), Ekman, S. (Simon), Mellemgaard, A. (Anders), Hansen, K. H. (Karin Holmskov), Cicenas, S. (Saulius), Koivunen, J. (Jussi), Grønberg, B. H. (Bjørn Henning), Sørensen, B. S. (Boe Sandahl), Brustugun, O. T. (Odd Terje)

Background: Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) patients. The efficacy of the drug in patients with mutations other than the common deletion in exon 19 and L858R in exon 21 is largely unknown. Methods:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2423::37a3719dc0d296304dc965ba5df47c51
http://urn.fi/urn:nbn:fi-fe2023062965858

Impact of comorbidity and venous thromboembolism on outcome in real-life non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibition (ICI)

Autor: Bjoernhart, B., Kristiansen, C., Hansen, K. H., Wedervang, K., Nyhus, C. H., Jorgensen, T. L., Herrstedt, J., Schytte, T.

Publikováno v: Bjoernhart, B, Kristiansen, C, Hansen, K H, Wedervang, K, Nyhus, C H, Jorgensen, T L, Herrstedt, J & Schytte, T 2020, ' Impact of comorbidity and venous thromboembolism on outcome in real-life non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibition (ICI) ', Annals of Oncology, vol. 31, no. Suppl. 7, 54P, pp. S1437 . https://doi.org/10.1016/j.annonc.2020.10.541

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::863a06d082c2384e4424e39348887b0f
https://portal.findresearcher.sdu.dk/da/publications/62a8563c-c261-4a4c-854c-c67cc4ab3673

The influence of polypharmacy on outcome in real life non-small cell lung cancer (NSCLC) patients treated with immunotherapy

Autor: Bjørnhart, Birgitte, Hansen, K. H., Jørgensen, Trine Lembrecht, Herrstedt, Jørn

Publikováno v: Bjørnhart, B, Hansen, K H, Jørgensen, T L & Herrstedt, J 2020, ' The influence of polypharmacy on outcome in real life non-small cell lung cancer (NSCLC) patients treated with immunotherapy ', Annals of Oncology, vol. 31, no. Suppl. 4, 1333P . https://doi.org/10.1016/j.annonc.2020.08.1647

Background Optimizing clinical selection of NSCLC patients expected to benefit from immune check-point inhibition (ICI) is necessary since only a minority of patients obtain durable long-term responses. Most NSCLC patients are > 70 years old with sub

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::7cce2dbbedcb2a913c1e237e99097afc
https://portal.findresearcher.sdu.dk/da/publications/236b2d32-1a07-4989-9b69-c71272863470

1958 Chevrolet LEVEL AIR SUSPENSION

Autor: Hansen, K. H., Bertsch, J. F., Denzer, R. E.

Publikováno v: SAE Transactions, 1958 Jan 01. 66, 483-490.

Externí odkaz: https://www.jstor.org/stable/44554171